Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important
modality in the therapeutic armamentarium of advanced, metastatic or inoperable …

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, arising from cells
of the endocrine system, with various clinical behaviors. Although these neoplasms are …

Continuous progress in the diagnostics and treatment of neuroendocrine neoplasms
(NENs), the emerging results of new clinical trials, and the new guidelines issued by medical …

ABSTRACT 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is now
approved for patients with advanced gastroenteropancreatic neuroendocrine tumors (NET) …

Introduction One of the concepts of theranostics in nuclear medicine is peptide receptor
radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging …

Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the
treatment of neuroendocrine tumors. Although there are no prospective randomized trials …

Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors, originating mostly
from the gastro-entero-pancreatic (GEP) tract followed by the lungs. Multidisciplinary …

Importance Peptide receptor radionuclide therapy (PRRT) is a tumor-targeted treatment that
uses radiation to induce tumor cell death in neuroendocrine tumors (NET) via β particle …

The development of diagnostic methods in medicine as well as the progress in the synthesis
of biologically active compounds allows the use of selected radioisotopes for the …

Because of different physical properties, the β-emitters 177Lu and 90Y offer specific
radiologic–biologic advantages in dedicated clinical situations. Our objective was to …